tiprankstipranks
Trending News
More News >
Organon (OGN)
NYSE:OGN
US Market
Advertisement

Organon (OGN) Earnings Dates, Call Summary & Reports

Compare
1,090 Followers

Earnings Data

Report Date
Feb 12, 2026
Before Open (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
0.76
Last Year’s EPS
0.9
Same Quarter Last Year
Moderate Sell
Based on 4 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 10, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong operational metrics like adjusted EBITDA margin and free cash flow, alongside significant challenges in key segments like Nexplanon and respiratory, leading to a downward revenue guidance revision. The divestiture of Jada offers potential for financial improvement, but the impact of past sales practices remains a concern.
Company Guidance
During the Organon third quarter 2025 earnings call, the company provided guidance that reflects several financial metrics and strategic priorities. The company reported third quarter revenue of $1.6 billion, with adjusted EBITDA at $518 million, resulting in an adjusted EBITDA margin of 32.3%. For the full year 2025, Organon revised its revenue guidance to a range of $6.2 billion to $6.25 billion, indicating a year-over-year nominal decline of 3.2% to 2.4%. The company expects adjusted gross margin to remain between 60% and 61% and adjusted EBITDA margin to be approximately 31% for the full year. Interest expense for 2025 is projected to be $510 million, with a non-GAAP tax rate estimated between 22.5% and 24.5%. The company also discussed its strategy of deleveraging, driving cost savings, and achieving revenue growth, while addressing recent sales practice issues that resulted in limited financial impact. Organon anticipates flat revenue growth for Nexplanon in 2026, factoring in policy headwinds and the impact of its 5-year launch.
Strong Adjusted EBITDA Margin
Adjusted EBITDA for the third quarter was $518 million, representing a healthy margin of 32.3%, indicating strong operational efficiency despite headwinds.
Biosimilars Growth
Year-to-date performance driven by Hadlima, up 63% ex-FX globally, and an international tender for Ontruzant. The new denosumab biosimilar was approved and launched in the U.S.
Positive Free Cash Flow
Year-to-date, delivered $813 million of free cash flow before one-time costs, demonstrating strong cash generation capabilities.
Strategic Divestiture of Jada System
Organon entered into a definitive agreement to divest the Jada system for $440 million, plus an additional $25 million contingent on 2026 revenue targets, enhancing financial flexibility.

Organon (OGN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

OGN Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Feb 12, 2026
2025 (Q4)
0.76 / -
0.9
Nov 10, 2025
2025 (Q3)
0.94 / 1.01
0.8716.09% (+0.14)
Aug 05, 2025
2025 (Q2)
0.95 / 1.00
1.12-10.71% (-0.12)
May 01, 2025
2025 (Q1)
0.89 / 1.02
1.22-16.39% (-0.20)
Feb 13, 2025
2024 (Q4)
0.87 / 0.90
0.882.27% (+0.02)
Oct 31, 2024
2024 (Q3)
0.90 / 0.87
0.870.00% (0.00)
Aug 06, 2024
2024 (Q2)
1.08 / 1.12
1.31-14.50% (-0.19)
May 02, 2024
2024 (Q1)
0.98 / 1.22
1.0812.96% (+0.14)
Feb 15, 2024
2023 (Q4)
0.81 / 0.88
0.818.64% (+0.07)
Nov 02, 2023
2023 (Q3)
1.05 / 0.87
1.32-34.09% (-0.45)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

OGN Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 10, 2025
$6.76$7.69+13.73%
Aug 05, 2025
$9.62$8.36-13.14%
May 01, 2025
$12.84$9.38-26.92%
Feb 13, 2025
$14.33$15.91+11.03%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Organon (OGN) report earnings?
Organon (OGN) is schdueled to report earning on Feb 12, 2026, Before Open (Confirmed).
    What is Organon (OGN) earnings time?
    Organon (OGN) earnings time is at Feb 12, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is OGN EPS forecast?
          OGN EPS forecast for the fiscal quarter 2025 (Q4) is 0.76.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis